Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Posterior staphyloma risk and anatomy in Europeans with high myopia

Official title: Risk of Posterior Staphyloma in Highly Myopic Europeans : From Epidemiology to Anatomy.

Run by Assistance Publique - Hôpitaux de Paris · NCT06949579 · Data updated 2026-11-12

This project will try to find genetic differences and blood markers linked to posterior staphyloma in adults of European descent who have high myopia.

More High Myopia trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment200 (estimated)
SponsorAssistance Publique - Hôpitaux de Paris
Academic / other
Locations1 site (Paris)
StatusRecruiting
StartedFebruary 12, 2026
Main results expectedDecember 2027
Study endsDecember 2027
Registry record updatedAugust 7, 2026
Trial IDNCT06949579 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18 years) of European ancestry with high myopia (axial length ≥26.0 mm or ≤ −6.0 diopters), good-quality retinal imaging, the ability to consent, and social security coverage are ideal candidates.

Probably not a fit

Patients with systemic or ocular conditions affecting the posterior segment (for example diabetes, systemic inflammatory disease, retinitis pigmentosa, syndromic or genetically-associated myopia) are excluded and are unlikely to benefit from this genetic-focused project.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multi-center, cross-sectional project will enroll 600 European adults with high myopia across three centers in France, Spain, and the Netherlands and collect blood for DNA and standardized retinal imaging. Participants will be divided into 300 with posterior staphyloma and 300 without, and a genome-wide association study (GWAS) will compare SNP frequencies between the two groups while adjusting for age, sex, axial length, and genetic ancestry. Significant loci will undergo functional annotation and pathway enrichment analyses, and exploratory analyses will relate genetic findings to retinal imaging phenotypes. All clinical and genetic data will be entered into a centralized Castor database under a harmonized protocol to ensure uniform phenotyping.

Why it matters

Potential benefit: If successful, the findings could help identify people at higher genetic risk for posterior staphyloma and point to biological pathways that may enable earlier monitoring or guide future treatments.

How similar studies have gone: Large GWAS have successfully identified genetic risk factors for general myopia, but applying GWAS specifically to posterior staphyloma in well-phenotyped European cohorts is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults with high myopia (axial length ≥ 26.00 mm or degree of myopia of at least -6 diopters), with and without posterior staphyloma

  * Adults aged 18 years or over
  * Patient with high myopia (axial length ≥ 26.00 mm or degree of myopia of at least -6 diopters), with good quality retinal imaging
  * Patient who has signed a consent form to participate in the study
  * Patient who is a beneficiary of a social security scheme or who is entitled to it

Exclusion Criteria:

* Any systemic or ocular pathologies with an impact on the posterior segment of the eye

  * Patient with a systemic pathology likely to affect the posterior segment of the eye:
  * Diabetes
  * Systemic inflammatory disease: sarcoidosis, rheumatoid arthritis, systemic lupus erythematosus, Horton's disease
  * Patients with retinitis pigmentosa
  * Patients with syndromic myopia
  * Patients with myopia associated with a genetic disease such as hereditary vitreoretinopathy
  * Patients under guardianship, curatorship or legal protection, as well as pregnant or breastfeeding women (article L1121-5 of the CSP).

Where it's running

  • Cochin Hospital
    Paris, France
    Recruiting

Study contacts

  • Principal investigator: Francine BEHAR-COHEN, MD,PhD — Assistance Publique - Hôpitaux de Paris
  • Study coordinator: Francine Behar-Cohen, MD, PhD
  • Email: francine.cohen@aphp.fr
  • Phone: 06 60 97 44 19

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.